|Bid||3.41 x 1800|
|Ask||3.42 x 1400|
|Day's Range||3.35 - 3.50|
|52 Week Range||1.58 - 3.93|
|Beta (3Y Monthly)||-0.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.20|
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.
In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis. Losses increased due to rising operating expenses and an unfavorable shift in product mix. The company reported operating expenses of $22.25 million in H1 2018, a YoY rise of 6%, which is mainly attributable to a 12% YoY rise in research and development expenses associated with pipeline products.
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.
Antares Pharma (ATRS) rose a solid 15.64% from $3.26 on October 1 to $3.77 on October 2. On October 1, 2018, the company announced that its Xyosted injection coupled with the QuickShot auto injector has gotten FDA approval as a testosterone replacement therapy in three dosage strengths of 50 mg, 75 mg, and 100 mg. As noted in Antares Pharma’s press release, Symphony Health Solutions has estimated the total number of retail prescriptions in the testosterone replacement market in 2017 at around 6.5 million. Antares Pharma closed at $3.77 on October 2, 2018, which was 138.61% higher than its 52-week low price of $1.58 and 7.82% lower than its 52-week high price of $4.09.
Antares received approval for its drug/device combo designed to be taken by patients once a week in their home to treat testosterone deficiencies.
The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected. The drug, however, comes with a boxed warning - the FDA's strongest - flagging risks of a rise in blood pressure that can cause major cardiovascular events. The FDA had declined to approve the drug, Xyosted, in October last year, highlighting elevated blood pressure, depression and suicidal tendencies in patients.
Antares Pharma, Inc. (ATRS) today announced the approval of XYOSTED™ (testosterone enanthate) injection by the U.S. Food and Drug Administration (FDA). XYOSTED™ is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot® auto injector. XYOSTED™ has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (see Indications and Usage below). “Today’s FDA approval of XYOSTED is a significant milestone for Antares.
Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:00 a.m. Eastern Time. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injection technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG) and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products include OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
When Antares Pharma Inc (NASDAQ:ATRS) announced its most recent earnings (30 June 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera ...
Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H. C. Wainwright & Co. LLC., on Thursday, September 6, 2018 at 3:50 p.m. Eastern Time. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injection technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary products include OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.
On August 16, 2018 the FDA granted approval of Teva’s (TEVA) epinephrine auto-injector for severe allergies. Both the 0.3 mg and the 0.15 mg (EpiPen Jr) were approved, receiving an AB equivalency rating. Teva did not provide details on timing or price, however, Teva has product ready to distribute and should only take only a short time (after printing up the package inserts) to stock the generic version in the drugstore.
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Biotech stocks Antares Pharma rose marginally and Adamis Pharmaceuticals was in the red on Thursday after news of Teva receiving FDA approval for its generic version of the EpiPen. Antares Pharma, Inc. shares closed up 4.10% on Thursday with an additional 3.33% in gains in after-hours trading. The company announced yesterday that it's partner Teva Pharmaceutical Industries has had its epinephrine auto injector drug-device combination product for emergency treatment of severe allergic reactions, approved by the Food and Drug Administration.
EWING, N.J., Aug. 16, 2018-- Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration has approved Teva Pharmaceutical Industries, Ltd.’ s epinephrine auto injector drug-device combination ...
Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies' stock prices to appreciate as they draw closer to their respective catalysts. Let's take a closer look at Kala Pharma (NASDAQ:KALA), TherapeuticsMD (NASDAQ:TXMD), and Antares Pharma (NASDAQ:ATRS). Biotech investor anticipation will be high on Friday, August 24, where Kala's Inveltys will be in the spotlight.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (ATRS) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and October 12, 2017. Antares, a specialty pharmaceutical company, develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. According to the complaint, on December 21, 2016, Antares announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA") and spoke optimistically about the drug's potential.
On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 3 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
EWING, N.J., Aug. 07, 2018-- Antares Pharma, Inc. today reported operating and financial results for the second quarter ended June 30, 2018. The Company reported revenue of $14.2 million and a net loss ...
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Antares Pharma, Inc. (NASDAQ: ATRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...
Antares Pharma, Inc. (ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of Research & Development, Chief Medical Officer effective August 6, 2018. Dr. Tursi has a diversified corporate background including 15 years of drug development experience within the biotech and pharmaceutical industry. Most recently, Dr. James Tursi was the Chief Medical Officer of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since October 1, 2015. Prior to Aralez, James served as Chief Medical Officer of Innocoll AG where he was responsible for managing all clinical research and development, medical affairs and safety activities for product candidates and medical devices which utilized a proprietary collagen-based technology.